Linked Life Data

18492115

Source:http://linkedlifedata.com/resource/pubmed/id/18492115

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18492115rdf:typepubmed:Citationlld:pubmed
pubmed-article:18492115lifeskim:mentionsumls-concept:C0008059lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0332835lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0301944lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0026565lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0009488lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0026538lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C1521828lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C0750502lld:lifeskim
pubmed-article:18492115lifeskim:mentionsumls-concept:C1518371lld:lifeskim
pubmed-article:18492115pubmed:issue2lld:pubmed
pubmed-article:18492115pubmed:dateCreated2009-9-15lld:pubmed
pubmed-article:18492115pubmed:abstractTextTreosulfan is an immuno-suppressive and myeloablative alkylating agent that has been introduced as a conditioning agent in stem cell transplantation (SCT). Most studies have been performed in adult patients with malignancy where a low incidence of regimen-related toxicity has been reported. We report the use of treosulfan in 32 consecutive children undergoing SCT for non-malignant disease. Patients received a total treosulfan dose of 36 or 42 g/m(2)/patient given in three daily, divided doses. A range of other conditioning agents and serotherapy was administered to patients who underwent family donor SCT (n = 11), or unrelated donor SCT (n = 21). One patient (3%) died early. Transplant morbidity was limited and mucositis was only mild. Dermatological toxicity was frequent but mild. Twenty-eight patients (87.5%) established donor cell engraftment. In 25 patients (78%) there was adequate, stable donor engraftment. Four patients have required additional transplant procedures to maintain adequate donor-derived haemopoiesis. Twenty-seven patients (84%) survive with a median follow up of 417 d. There were four late deaths due to progression of the underlying disease, graft-versus-host disease or infection. Treosulfan-based conditioning regimens achieve excellent engraftment with reduced regimen-related toxicity in children with non-malignant disease at high risk for both regimen-related toxicity and graft failure.lld:pubmed
pubmed-article:18492115pubmed:languageenglld:pubmed
pubmed-article:18492115pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18492115pubmed:citationSubsetIMlld:pubmed
pubmed-article:18492115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18492115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18492115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18492115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18492115pubmed:statusMEDLINElld:pubmed
pubmed-article:18492115pubmed:monthJunlld:pubmed
pubmed-article:18492115pubmed:issn1365-2141lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:OoiHHlld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:WynnRobert...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:CarrTrevor...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:GharibMagedMlld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:GouldenNichol...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:BonanomiSonia...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:RaoKanchanaKlld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:AmroliaPersis...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:VeysPaul APAlld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:CoussonsMaryMlld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:KhalidTasneem...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:GreystokeBrig...lld:pubmed
pubmed-article:18492115pubmed:authorpubmed-author:JaganiMamtaMlld:pubmed
pubmed-article:18492115pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18492115pubmed:volume142lld:pubmed
pubmed-article:18492115pubmed:ownerNLMlld:pubmed
pubmed-article:18492115pubmed:authorsCompleteYlld:pubmed
pubmed-article:18492115pubmed:pagination257-62lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:meshHeadingpubmed-meshheading:18492115...lld:pubmed
pubmed-article:18492115pubmed:year2008lld:pubmed
pubmed-article:18492115pubmed:articleTitleTreosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities.lld:pubmed
pubmed-article:18492115pubmed:affiliationDepartment of Blood and Marrow Transplant, Royal Manchester Children's Hospital, Manchester, UK.lld:pubmed
pubmed-article:18492115pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18492115pubmed:publicationTypeMulticenter Studylld:pubmed